What happened
Researchers at Washington University School of Medicine in St. Louis and the VA St. Louis Health Care System did something most studies never attempt. Instead of asking about one outcome, they mapped 175 health outcomes across more than 2 million people, comparing those on GLP-1 receptor agonists (the class that includes semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound) against people on older diabetes medicines.
The headline finding is a cluster of GLP-1 brain benefits. Dementia risk fell by roughly 8 percent and Alzheimer disease risk by about 12 percent. The drugs were also tied to lower risks of seizures, suicidal ideation, self-harm and some psychotic disorders. A June 2026 follow-up from the same group, published in The BMJ, sharpened the addiction signal: a 14 percent lower risk of developing any substance-use disorder, and among people who already had one, a 40 percent reduction in overdoses and a 50 percent reduction in drug-related deaths. The lead author, clinical epidemiologist Ziyad Al-Aly, has called it quieting the "drug noise" that drives craving.
Why this matters for women
None of this comes free, and the same study is honest about it. GLP-1 medicines carried higher risks of pancreatitis, certain kidney problems, and the gastrointestinal effects most women already know: nausea, vomiting, diarrhea, and rarely a slowing of the stomach. Most of the benefits are modest, in the 10 to 20 percent range, not miracles.
What makes the brain findings land for women is who these conditions hit hardest. Alzheimer disease, depression and anxiety all fall more heavily on women than men. A medicine taken for the scale that also nudges those risks downward is a different kind of news than a smaller waistband.
The likely reason ties several Steady threads together. Al-Aly points to two mechanisms: weight loss and lower inflammation in the brain. We have written about how GLP-1 medicines calm inflammation throughout the body, and about the broader picture of GLP-1 and long-term brain health. The cooling of food noise and craving many women describe may be the same reward-pathway effect, viewed from the inside.
What it means for you
Read this as encouragement, not as a reason to chase a dose. The brain benefits show up at ordinary treatment doses, as a quiet side effect of steady use, not something you earn by pushing harder. The honest risks are real, which is exactly why they belong in a calm conversation with your prescriber rather than a headline.
Bring the whole picture. If you have noticed steadier moods or quieter cravings, that is worth saying out loud. If you have had stomach pain that wraps to your back, or you are well into titration, that belongs in the same conversation. Pancreatitis and kidney signals are uncommon but matter.
What Steady does with this
Steady tracks 14 GLP-1 symptoms, including mood changes and stomach pain, alongside your dose and your cycle. When you sit down with your prescriber, your month is already one clear page: what shifted, when, and on which dose. The scale is the least interesting number on it. What you keep, steadiness included, is the real outcome.
